Burdens call for alternatives in the landscape of options ….
Challenges Facing All Stakeholders in Mental Healthcare
People
Health Providers
Insurance Providers
Governments
Adult with Depression
Covid Mental Strain
Mental Health Spending
| COMPOUND | BETR-001 | PSILOCYBIN | LSD | MDMA |
|---|---|---|---|---|
| CSA Schedule 1 Drug | No | Yes | Yes | Yes |
| Multiple Formal Human Studies | Yes | Yes | Yes | Yes |
| Hallucinogenic Effects | No | Yes | Yes | Low/No |
| USDOJ List 1 Precursors | No | Yes | Yes | Yes |
| UN Convention Illicit Drug | No | Yes | Yes | Yes |
| Patient Self-Administered | Yes | No | No | No |
| Regulatory Hurdle(s) | Low | High | High | High |
Pipeline and Indications Program
Pipeline and Indications Program
We are developing first-in-class, 2nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need
Compound Name: BETR-001
Product Name: E559 [proprietary 2-bromo-LSD compound]
Delivery: Oral, Capsule
Description: AA first-in-class, non-hallucinogenic, second-generation LSD derivative.
Indications: MDD, Anxiety, Neuropathic Pain
Patents: Issued and Pending
Compound Name: BETR-002
Product Name: Dihydrohonokiol-B (DHH-B)
Delivery: Oral Capsule
Description: A derivative of hydrohonokiol, a known anxiolytic compound.
Indications: Benzodiazepine Dependency, Anxiety, Neurodegenerative disorders
Patents: Pending
Pipeline |
||||||
|---|---|---|---|---|---|---|
Program |
Discovery | Preclinical | IND | Phase I | Phase II | Phase III |
|
Major Depressive Disorder
BETR-001
|
|
|||||
|
Anxiety Disorder
BETR-001
|
|
|||||
|
Neuropathic Pain
BETR-001
|
|
|||||
|
Benzodiazepine Dependency
BETR-002
|
|
|||||
References
- https://www.nature.com/articles/d41586-021-00175-z
- https://mhanational.org/sites/default/files/2021%20State%20of%20Mental%20Health%20in%20America_0.pdf
- https://finance.yahoo.com/news/why-mental-health-care-in-america-is-so-shoddy-183448311.html
Clinical Process
Study Design
Customized & Protocol Based
Drug Development
Proactive & Data Driven
Trial Execution
Transparent & Compliant
Regulatory Submission
Complete & Timely
The unmet mental health footprint is immense. Our programs start and end with patients first, driving us for continuous solutions. We will expand our programs to address other indications, timely and progressively!
BetterLife also owns a drug candidate, for the treatment of viral infections such as COVID-19,
through its wholly owned subsidiary MedMelior.